Amgen Inc. (NASDAQ:AMGN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...
The American Journal of Managed Care4d
Phase 3 Data Support Nipocalimab for Myasthenia Gravis
The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...
STAT5d
Previewing Immunovant’s myasthenia gravis study readout — with all its quirky nuance
It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.
Immunovant, Inc. (NASDAQ:IMVT) Shares Bought by KBC Group NV
KBC Group NV boosted its position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 60.1% in the 4th quarter, ...
SG Americas Securities LLC Has $220,000 Stake in argenx SE (NASDAQ:ARGX)
SG Americas Securities LLC increased its position in argenx SE (NASDAQ:ARGX – Free Report) by 6.2% in the 4th quarter, ...
IMVT Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus
Immunovant stock down on dismal third-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.
pharmaphorum3d
Sanofi drops BTK drug tolebrutinib in myasthenia gravis
Myasthenia gravis is a serious, rare, and chronic neuromuscular autoimmune disease that can cause debilitating and potentially life-threatening muscle weakness. There are around 60,000 to 120,000 ...
pharmaphorum2d
UCB bags FDA approval for second myasthenia gravis drug
Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG ... and neuromuscular disease. Zilbrysq (zilucoplan), billed ...